Abstract:Extra domain B of fibronectin (FN-EDB) is upregulated in the extracellular matrix during tissue remodeling and has been postulated as a potential biomarker for atherosclerosis, yet no systematic test for FN-EDB in plaques has been reported. We hypothesized that FN-EDB expression would intensify in advanced plaques. Furthermore, engineering of FN-EDB-targeted nanoparticles (NPs) could enable imaging/diagnosis and local delivery of payloads to plaques. Methods: The amount of FN-EDB in human atherosclerotic and normal arteries (ages: 40 to 85 years) was assessed by histological staining and quantification using an FN-EDB-specific aptide (APTFN-EDB). FN-EDB-specific NPs that could serve as MRI beacons were constructed by immobilizing APTFN-EDB on the NP surface containing DTPA[Gd]. MRI visualized APTFN-EDB-[Gd]NPs administered to atherosclerotic apolipoprotein E-deficient mice in the brachiocephalic arteries. Analysis of the ascending-to-descending thoracic aortas and the aortic roots of the mice permitted quantitation of Gd, FN-EDB, and APTFN-EDB-[Gd]NPs. Cyanine, a model small molecule drug, was used to study the biodistribution and pharmacokinetics of APTFN-EDB-NPs to evaluate their utility for drug delivery. Results: Atherosclerotic tissues had significantly greater FN-EDB-positive areas than normal arteries (P < 0.001). This signal pertained particularly to Type III (P < 0.01), IV (P < 0.01), and V lesions (P < 0.001) rather than Type I and II lesions (AHA classification). FN-EDB expression was positively correlated with macrophage accumulation and neoangiogenesis. Quantitative analysis of T1-weighted images of atherosclerotic mice revealed substantial APTFN-EDB-[Gd]NPs accumulation in plaques compared to control NPs, conventional MRI contrast agent (Gd-DTPA) or accumulation in wild-type C57BL/6J mice. Additionally, the APTFN-EDB-NPs significantly prolonged the blood-circulation time (t1/2: ~ 6 h) of a model drug and increased its accumulation in plaques (6.9-fold higher accumulation vs. free drug). Conclusions: Our findings demonstrate augmented FN-EDB expression in Type III, IV, and V atheromata and that APTFN-EDB-NPs could serve as a platform for identifying and/or delivering agents locally to a subset of atherosclerotic plaques.

Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.

Inhibited Atherosclerotic Plaque Formation by Local Administration of Magnetically Labeled Endothelial Progenitor Cells (epcs) in a Rabbit Model.

Intravascular Magnetic Resonance/radiofrequency May Enhance Gene Therapy for Prevention of In-Stent Neointimal Hyperplasia.

Inflammatory Endothelium-Targeted and Cathepsin Responsive Nanoparticles Are Effective Against Atherosclerosis

Abstract 300: Mangiferin Conjugated Gold Nanoparticles Protect Against The Development Of Abdominal Aortic Aneurysm In Apoe–/– Mouse Model

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

Oral nanoparticles containing naringenin suppress atherosclerotic progression by targeting delivery to plaque macrophages

A nanotherapy responsive to the inflammatory microenvironment for the dual-targeted treatment of atherosclerosis

Nanoparticles Targeting Extra Domain B of Fibronectin-Specific to the Atherosclerotic Lesion Types III, IV, and V-enhance Plaque Detection and Cargo Delivery.

Metformin attenuates Angiotensin II induced cardiac fibrosis and cardiac connective tissue growth factor (CTGF) expression through AMP-activated protein kinase activation

Endothelium-targeted NF-κB siRNA nanogel for magnetic resonance imaging and visualized-anti-inflammation treatment of atherosclerosis

Anti-inflammatory Nanoparticle for Prevention of Atherosclerotic Vascular Diseases

Fibroblast-Mimicking Nanodecoys for Multi-Target Antiangiogenesis in the Inflammation Treatment

Abstract 139: Precision Nanomedicine Targeting Novel Endothelial Mechano-sensing Mechanisms To Treat Vascular Diseases

Molecularly Imprinted Nanomedicine for Anti-angiogenic Cancer Therapy Via Blocking Vascular Endothelial Growth Factor Signaling.

Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI)

Abstract P408: Mesenchymal Stem Cell-derived Angptl4 Improves Endothelial Permeability And Resolution Of Inflammation In Atherosclerosis

Fumagillin inhibits colorectal cancer growth and metastasis in mice:an in vivo and in vitro study of antiangiogenesis

EGFP-EGF1-conjugated poly(lactic-co-glycolic acid) nanoparticles, a new diagnostic tool and drug carrier for atherosclerosis

Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis.